Human Ectonucleoside triphosphate diphosphohydrolase 1(ENTPD1) ELISA kit

Code CSB-EL007690HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
ectonucleoside triphosphate diphosphohydrolase 1
Alternative Names
ATPDase ELISA Kit; CD 39 ELISA Kit; CD39 ELISA Kit; CD39 antigen ELISA Kit; DKFZp686D194 ELISA Kit; DKFZp686I093 ELISA Kit; Ecto apyrase ELISA Kit; Ecto ATP diphosphohydrolase ELISA Kit; Ecto-apyrase ELISA Kit; Ecto-ATP diphosphohydrolase 1 ELISA Kit; Ecto-ATPase 1 ELISA Kit; Ecto-ATPDase 1 ELISA Kit; Ectonucleoside triphosphate diphosphohydrolase 1 ELISA Kit; ENTP1_HUMAN ELISA Kit; ENTPD 1 ELISA Kit; ENTPD1 ELISA Kit; FLJ40921 ELISA Kit; FLJ40959 ELISA Kit; Lymphoid cell activation antigen ELISA Kit; NTPDase 1 ELISA Kit; NTPDase1 ELISA Kit; SPG64 ELISA Kit
Abbreviation
ENTPD1
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
23.44 pg/mL-1500 pg/mL
Sensitivity
5.86 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Others
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human ENTPD1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %84
Range %81-89
1:2Average %97
Range %93-102
1:4Average %84
Range %80-88
1:8Average %99
Range %95-102
Recovery
The recovery of human ENTPD1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 10097-103
EDTA plasma (n=4)107103-110
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
15002.161 2.343 2.252 2.059
7501.724 1.708 1.716 1.523
3751.296 1.274 1.285 1.092
187.50.891 0.885 0.888 0.695
93.750.562 0.598 0.580 0.387
46.880.401 0.421 0.411 0.218
23.440.287 0.289 0.288 0.095
00.191 0.194 0.193
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human ENTPD1 ELISA Kit was designed for the quantitative measurement of Human ENTPD1 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 23.44 pg/mL-1500 pg/mL and the sensitivity is 5.86 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well.
Gene References into Functions
  1. Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
  2. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. PMID: 30006565
  3. CD39 expression and activity is attenuated in lung tissue of chronic obstructive pulmonary disease patients. PMID: 29807526
  4. monocyte-derived macrophages from ankylosing spondylitis patients expressed reduced levels of CD39 mRNA compared to those from healthy controls PMID: 29524036
  5. expression in primary lesions and metastatic lymph nodes seems to identify patients at high risk in squamous cell carcinoma of the head and neck PMID: 29172836
  6. ur results demonstrate that CD39 is upregulated on conventional CD4+ and CD8+ T cells at sites of acute infection and inflammation, and that CD39 dampens responses to bacterial infection. PMID: 29742141
  7. this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
  8. The peripheral blood mononuclear cells (PBMC) from the transgenic pigs were more resistant to lysis by pooled complement-preserved normal human serum than that from wild type (WT) pig. Accordingly, GGTA1 mutated piglets expressing hCD39 will provide a new organ source for xenotransplantation research PMID: 27830476
  9. Phosphoantigens (pAgs) induced expression of the ecto-ATPase CD39, which, however, not only hydrolyzed ATP but also abrogated the gammadelta T cell receptor (TCR) agonistic activity of self and microbial pAgs. PMID: 27346340
  10. These studies showed that the G allele of rs3176891 marks a haplotype associated with increased clotting and platelet aggregation attributable to a promoter variant associated with increased transcription, expression, and activity of NTPDase1. PMID: 28302652
  11. Transgenic expression of human CD39 is associated with increased renal fibrosis after ischemia in mice. PMID: 28198766
  12. CD39 overexpression protects against cerebral ischemia in a transgenic mouse model. PMID: 28377485
  13. Ablation of CD73 minimally effects in vivo thrombosis, but increased CD39 expression on hematopoietic-derived cells, especially monocytes, attenuates in vivo arterial thrombosis. PMID: 27417582
  14. Data show that Th17(CD39+) cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production in juvenile autoimmune liver disease (AILD). PMID: 27210814
  15. concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
  16. Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
  17. this study shows that T-cell expression of CD39 was higher in acute exacerbations of chronic obstructive pulmonary disease patients than stable COPD patients or healthy controls PMID: 27430193
  18. Pulmonary CD39 expression and activity are increased in COPD. Following acute cigarette smoke exposure CD39 was upregulated in BALF cells in smokers. PMID: 26541524
  19. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
  20. Increased inducibility of CD39 after activation may contribute to the impaired vaccine response with age. PMID: 26832412
  21. The altered function and expression of P2X7 and ART1 in the human CD39+ Treg or CD39- Treg cells could participate in the resistance against cell death induced by ATP or NAD. PMID: 26307000
  22. Despite the increased level of NTPDase1 and NTPDase3 mRNA expression in chondrogenically induced MSCs, their activity toward ATP remains quite low. PMID: 26018728
  23. the expression of CD39 on Treg cells and also in CD4(+)IL-17(+) cells from T2D patients is related to hyperglycemia as well as to overweight and obesity and therefore may participate as a modulator of the effector capacity of Th17 cells. PMID: 26386144
  24. We suggest modulation of human Th17 responsiveness by CD39 and CD161 and describe novel molecular mechanisms integrating elements of both extracellular nucleotide and sphingolipid homeostasis--{REVIEW} PMID: 26059452
  25. Findings provide insights into Tc1-mediated IFNgamma responses and ROS generation and link these pathways to CD39/adenosine-mediated effects in immunological disease. PMID: 26549640
  26. the current study revealed that malignant epithelial cells of human rectal adenocarcinoma strongly express CD39 that may play a potential role in the tumor invasion and metastasis. PMID: 26113408
  27. role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
  28. this study demonstrates that the expression of CD39 in Tregs is primarily genetically driven, and this may determine interindividual differences in the control of inflammatory responses. PMID: 25640206
  29. these data establish CD39 as a regionalized regulator of atherogenesis that is driven by shear stress. PMID: 26121751
  30. our data indicate that T-cell CD39 expression may identify subsets of patients with B-CLL with an unfavorable clinical outcome. PMID: 24684231
  31. The Na-K-2Cl cotransporter was downregulated by high-sodium diet in wild-type mice, but it increased in transgenic mice overexpressing human CD39 PMID: 25877509
  32. apelin, a known regulator of pulmonary vascular homeostasis, can potentiate the activity of CD39 both in vitro and in vivo PMID: 25820525
  33. Blackcurrant leaf extract increases endothelial cell NOS and CD39 levels in a concentration dependent manner. PMID: 25407137
  34. Data show that Rubus leave extracts significantly increased CD39 antigen NTPDase 1 ecto-ATP diphosphohydrolase 1 (CD39/NTPDase-1) expressions and decreased ATPDase activities. PMID: 25034034
  35. Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease. PMID: 25421756
  36. by regulating ATP availability at the cardiac mast cell surface surface, CD39 modulates local renin release and thus, renin-angiotensin system activation, ultimately exerting a cardioprotective effect PMID: 25318477
  37. Our data suggests that human bone marrow-derived mesenchymal stem cells can effectively suppress immune responses of the Th17 cells via the CD39-CD73-mediated adenosine-producing pathway PMID: 24043462
  38. ecto-nucleotidases CD39 and CD73 are expressed in human endometrial tumors PMID: 24707115
  39. FOXP3(+) CD39(+) Treg cells are enriched at the site of inflammation, do not produce proinflammatory cytokines, and are good suppressors of many effector T-cell functions including production of IFN-gamma, TNF, and IL-17F but do not limit IL-17A secretion PMID: 24990235
  40. CD39 and CD161 modulate human Th17 responses in CD through alterations in purinergic nucleotide-mediated responses and ASM catalytic bioactivity, respectively. PMID: 25172498
  41. The present findings suggest the existence of an endogenous anti-tissue destructive mechanism in gingival tissue via the CD39-adenosinergic axis. PMID: 23941770
  42. Results show the interplay between promoter SNPs of CD39 and FAM134B results in an intercellular epistasis which influences the risk of a complex inflammatory disease. PMID: 24970562
  43. The data indicates that glioma-derived CD73 contributes to local adenosine-mediated immunosuppression in synergy with CD39 from infiltrating CD4(+)CD39(+) T lymphocytes in human malignant gliomas. PMID: 23737488
  44. These data identify CD39 as a novel marker of human regulatory CD8(+) T cells and indicate that CD39 is functionally involved in suppression by CD8(+) Treg cells PMID: 23606272
  45. CD39 counteraction inhibits the suppression activity of CD8+ Treg (both from peripheral blood and tumor microenvironment) suggesting that CD39-mediated inhibition constitutes a prevalent hallmark of their function PMID: 23359087
  46. hCD39 expressed by circulating leukocytes and intrinsic renal cells limits innate AN injury. PMID: 22684996
  47. The expression of ENTPD1 and ecto-adenosine deaminase in lymphocytes of Chagase disease patients are reported. PMID: 22846899
  48. We demonstrate for the first time increased CD39 expression and function on circulating microparticles in patients with IPAH. PMID: 22792409
  49. identified hitherto unrecognized soluble forms of AK1 and NTPDase1/CD39 that contribute in the active cycling between the principal platelet-recruiting agent ADP and other circulating nucleotides PMID: 22637533
  50. These findings not only suggest that CD39 Treg cells may be involved in hepatitis B virus disease progression but also identify CD39 Tregs as a dynamic immune regulatory cell population that may represent a new target of immunomodulatory therapeutic interventions. PMID: 22489829

Show More

Hide All

Involvement in disease
Spastic paraplegia 64, autosomal recessive (SPG64)
Subcellular Location
Membrane; Multi-pass membrane protein.
Protein Families
GDA1/CD39 NTPase family
Tissue Specificity
Expressed primarily on activated lymphoid cells. Also expressed in endothelial tissues. Isoform 1 and isoform 3 are present in both placenta and umbilical vein, whereas isoform 2 is present in placenta only.
Database Links

HGNC: 3363

OMIM: 601752

KEGG: hsa:953

STRING: 9606.ENSP00000360250

UniGene: Hs.576612

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1